Princeton-based Syridex Bio, an impact-driven, life sciences-focused firm investing in therapies that address the needs of underserved communities, has officially launched. The firm’s founding, by a team of experts at the nexus of life sciences, entrepreneurship, and investing, reflects the need for investment intentionally directed toward addressing health inequities and the largely untapped potential for robust financial returns in this often-overlooked space.
Syridex Bio’s investment focus is on funding therapies for diseases that disproportionately affect underserved populations, including ethnic minorities, the LGBTQ+ community, and rural dwellers. The firm’s investment targets include in-development drugs and medical therapies that tackle the world’s greatest health outcome disparities.
Squire Servance, founder and managing partner, has spent more than a decade working in the biotechnology, pharmaceutical, and life sciences industries. Prior to founding Syridex, he served as senior vice president, general counsel & corporate secretary at Repligen Corporation, a bioprocessing-focused life sciences company, where he led the legal, corporate secretary, compliance, and enterprise risk functions. He also counseled the company’s Board of Directors and senior management. Servance joined Repligen from Baxter International, Inc. where he led the global legal team supporting its multi-billion-dollar global pharmaceuticals business.
“Syridex Bio is founded on the fundamental belief that everyone deserves the opportunity to live a healthy life,” said Servance. “Accelerating progress toward health equity requires unified action by a range of leaders and stakeholders, and it is increasingly clear that the investor community must play a central role. Driven by our focus on positive impact, we leverage a market-based approach to invest in therapies that intentionally serve the underserved – thus, laying the foundation for true equality in healthcare and opening the door to a brighter, healthier global future.”
The minority-led firm, guided by a world-class advisory board, draws on deep relationships across the global pharmaceutical and biotechnology industries to source investment opportunities in innovative, best-in-class clinical stage or near-clinical stage therapies.
The advisory board is led by:
To access more business news, visit NJB News Now.Related Articles: